Desde 500€ puedes invertir en Biocross a través de Blockchain
the life expectancy and quality of life of individuals with neurodegenerative diseases
through the design of innovative diagnostic systems.
and non-invasive diagnostic tools that can be used
at any stage of the disease.
Early diagnosis
Reliable
Non-invasive
Our goal
To provide neurologists with an integrated diagnostic solution that can be applied to any stage of the disease, including the earliest, asymptomatic phase.
Benefits
- Reduced cost of AD risk-assessment and diagnosis.
- More widespread testing thanks to simpler, more readily available diagnostic methods.
- Improved diagnosis, through earlier detection and differentiation of distinct dementia types.
- Simplified diagnosis through leveraging of existing laboratory equipment.
- Improved patient experience and safety.
The e4Risk® is a non-genetic, cost-effective, and highly reliable method to detect the presence of the ApoE4 protein in human blood plasma using high-throughput chemical analysis.
Biospain 2016 – Company Presentation
Biospain has become the main scientific, social, commercial, and industrial meeting point of the biotechnological sector and the primary platform for the international presentation of advances in Spanish biotechnology.
The Spanish entrepreneurs fighting against Alzheimer’s
The diagnosis of Alzheimer’s disease is established through a series of neuropsychological tests, images obtained by MRI or CT scan, and the analysis of markers obtained by lumbar puncture.
Biocross announces AAIC 2016 poster
Biocross is pleased to present at the 2016 Alzheimer’s Association International Conference® (AAIC®) in Toronto its work on the influence of APOE ε4 carrier status on the metabolomic profile of AD patients versus cognitively normal controls. The AAIC® is the world’s largest forum for the dementia research community.
If you have any questions or comments, we will be pleased to attend you
Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain
+34 983 54 98 96